BioWorld

April 3, 2007

Radius Attracts Series C Funds For Programs In Women's Health

Radius brought in $29 million from a potential $57.5 million Series C financing round, money that will be used to advance development of four programs targeting women's health. (BioWorld Today) Read More

Roche Acquires Therapeutic Human Polyclonals For $56.5M

New Possibilities For Taking On Ever-Looming Blood Shortage

Cephalon's Nuvigil Gets Nod; Label Change, No New Trials

Merrion Files For $46M IPO, Seeks Listing In U.S., Ireland

Bioenvision Raises $30M Via A Sale Of Registered Shares

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...